Diagnosing idiopathic learning disability: a cost-effectiveness analysis of microarray technology in the National Health Service of the United Kingdom.
Array based comparative genomic hybridisation (aCGH) is a powerful technique for detecting clinically relevant genome imbalance and can offer 40 to > 1000 times the resolution of karyotyping. Indeed, idiopathic learning disability (ILD) studies suggest that a genome-wide aCGH approach makes 1...
| Päätekijät: | , , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Journal article |
| Kieli: | English |
| Julkaistu: |
2007
|
| _version_ | 1826293541420138496 |
|---|---|
| author | Wordsworth, S Buchanan, J Regan, R Davison, V Smith, K Dyer, S Campbell, C Blair, E Maher, E Taylor, J Knight, S |
| author_facet | Wordsworth, S Buchanan, J Regan, R Davison, V Smith, K Dyer, S Campbell, C Blair, E Maher, E Taylor, J Knight, S |
| author_sort | Wordsworth, S |
| collection | OXFORD |
| description | Array based comparative genomic hybridisation (aCGH) is a powerful technique for detecting clinically relevant genome imbalance and can offer 40 to > 1000 times the resolution of karyotyping. Indeed, idiopathic learning disability (ILD) studies suggest that a genome-wide aCGH approach makes 10-15% more diagnoses involving genome imbalance than karyotyping. Despite this, aCGH has yet to be implemented as a routine NHS service. One significant obstacle is the perception that the technology is prohibitively expensive for most standard NHS clinical cytogenetics laboratories. To address this, we investigated the cost-effectiveness of aCGH versus standard cytogenetic analysis for diagnosing idiopathic learning disability (ILD) in the NHS. Cost data from four participating genetics centres were collected and analysed. In a single test comparison, the average cost of aCGH was pound442 and the average cost of karyotyping was pound117 with array costs contributing most to the cost difference. This difference was not a key barrier when the context of follow up diagnostic tests was considered. Indeed, in a hypothetical cohort of 100 ILD children, aCGH was found to cost less per diagnosis ( pound3,118) than a karyotyping and multi-telomere FISH approach ( pound4,957). We conclude that testing for genomic imbalances in ILD using microarray technology is likely to be cost-effective because long-term savings can be made regardless of a positive (diagnosis) or negative result. Earlier diagnoses save costs of additional diagnostic tests. Negative results are cost-effective in minimising follow-up test choice. The use of aCGH in routine clinical practice warrants serious consideration by healthcare providers. |
| first_indexed | 2024-03-07T03:31:42Z |
| format | Journal article |
| id | oxford-uuid:baf336a1-7bdd-4d83-b10f-76eca37c555f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:31:42Z |
| publishDate | 2007 |
| record_format | dspace |
| spelling | oxford-uuid:baf336a1-7bdd-4d83-b10f-76eca37c555f2022-03-27T05:13:28ZDiagnosing idiopathic learning disability: a cost-effectiveness analysis of microarray technology in the National Health Service of the United Kingdom.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:baf336a1-7bdd-4d83-b10f-76eca37c555fEnglishSymplectic Elements at Oxford2007Wordsworth, SBuchanan, JRegan, RDavison, VSmith, KDyer, SCampbell, CBlair, EMaher, ETaylor, JKnight, SArray based comparative genomic hybridisation (aCGH) is a powerful technique for detecting clinically relevant genome imbalance and can offer 40 to > 1000 times the resolution of karyotyping. Indeed, idiopathic learning disability (ILD) studies suggest that a genome-wide aCGH approach makes 10-15% more diagnoses involving genome imbalance than karyotyping. Despite this, aCGH has yet to be implemented as a routine NHS service. One significant obstacle is the perception that the technology is prohibitively expensive for most standard NHS clinical cytogenetics laboratories. To address this, we investigated the cost-effectiveness of aCGH versus standard cytogenetic analysis for diagnosing idiopathic learning disability (ILD) in the NHS. Cost data from four participating genetics centres were collected and analysed. In a single test comparison, the average cost of aCGH was pound442 and the average cost of karyotyping was pound117 with array costs contributing most to the cost difference. This difference was not a key barrier when the context of follow up diagnostic tests was considered. Indeed, in a hypothetical cohort of 100 ILD children, aCGH was found to cost less per diagnosis ( pound3,118) than a karyotyping and multi-telomere FISH approach ( pound4,957). We conclude that testing for genomic imbalances in ILD using microarray technology is likely to be cost-effective because long-term savings can be made regardless of a positive (diagnosis) or negative result. Earlier diagnoses save costs of additional diagnostic tests. Negative results are cost-effective in minimising follow-up test choice. The use of aCGH in routine clinical practice warrants serious consideration by healthcare providers. |
| spellingShingle | Wordsworth, S Buchanan, J Regan, R Davison, V Smith, K Dyer, S Campbell, C Blair, E Maher, E Taylor, J Knight, S Diagnosing idiopathic learning disability: a cost-effectiveness analysis of microarray technology in the National Health Service of the United Kingdom. |
| title | Diagnosing idiopathic learning disability: a cost-effectiveness analysis of microarray technology in the National Health Service of the United Kingdom. |
| title_full | Diagnosing idiopathic learning disability: a cost-effectiveness analysis of microarray technology in the National Health Service of the United Kingdom. |
| title_fullStr | Diagnosing idiopathic learning disability: a cost-effectiveness analysis of microarray technology in the National Health Service of the United Kingdom. |
| title_full_unstemmed | Diagnosing idiopathic learning disability: a cost-effectiveness analysis of microarray technology in the National Health Service of the United Kingdom. |
| title_short | Diagnosing idiopathic learning disability: a cost-effectiveness analysis of microarray technology in the National Health Service of the United Kingdom. |
| title_sort | diagnosing idiopathic learning disability a cost effectiveness analysis of microarray technology in the national health service of the united kingdom |
| work_keys_str_mv | AT wordsworths diagnosingidiopathiclearningdisabilityacosteffectivenessanalysisofmicroarraytechnologyinthenationalhealthserviceoftheunitedkingdom AT buchananj diagnosingidiopathiclearningdisabilityacosteffectivenessanalysisofmicroarraytechnologyinthenationalhealthserviceoftheunitedkingdom AT reganr diagnosingidiopathiclearningdisabilityacosteffectivenessanalysisofmicroarraytechnologyinthenationalhealthserviceoftheunitedkingdom AT davisonv diagnosingidiopathiclearningdisabilityacosteffectivenessanalysisofmicroarraytechnologyinthenationalhealthserviceoftheunitedkingdom AT smithk diagnosingidiopathiclearningdisabilityacosteffectivenessanalysisofmicroarraytechnologyinthenationalhealthserviceoftheunitedkingdom AT dyers diagnosingidiopathiclearningdisabilityacosteffectivenessanalysisofmicroarraytechnologyinthenationalhealthserviceoftheunitedkingdom AT campbellc diagnosingidiopathiclearningdisabilityacosteffectivenessanalysisofmicroarraytechnologyinthenationalhealthserviceoftheunitedkingdom AT blaire diagnosingidiopathiclearningdisabilityacosteffectivenessanalysisofmicroarraytechnologyinthenationalhealthserviceoftheunitedkingdom AT mahere diagnosingidiopathiclearningdisabilityacosteffectivenessanalysisofmicroarraytechnologyinthenationalhealthserviceoftheunitedkingdom AT taylorj diagnosingidiopathiclearningdisabilityacosteffectivenessanalysisofmicroarraytechnologyinthenationalhealthserviceoftheunitedkingdom AT knights diagnosingidiopathiclearningdisabilityacosteffectivenessanalysisofmicroarraytechnologyinthenationalhealthserviceoftheunitedkingdom |